Significant Ownership of Sofinnova Partners SAS

Location
Paris, France
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Sofinnova Partners SAS.

Notify me when Sofinnova Partners SAS files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Sofinnova Partners SAS

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
QNCX Quince Therapeutics, Inc. Common Stock, par value $0.001 per share 2.7% $1,185,734 -$1,188,000 1,197,711 -50% Sofinnova Capital VIII 31 Mar 2025

Schedules 13D/G Reported by Sofinnova Partners SAS:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.